Cancer/Tumor Profiling Market Worth $16.0 Billion by 2027 - Exclusive Report by MarketsandMarkets™
In May 2022, QIAGEN launched the therascreen EGFR Plus RGQ PCR Kit, a new in-vitro diagnostic test for sensitive EGFR mutation analysis, empowering oncologists to guide non-small cell lung cancer (NSCLC) treatment better.
View full press release